ReviewCell communication and signaling : CCS2023
The dual role of microRNA (miR)-20b in cancers: Friend or foe?
Review in Cell communication and signaling : CCS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Chrysin treatment is associated with altered microrna expression and reduced levels of HPV16 E6 protein in caski cervical cancer cells.Medical oncology (Northwood, London, England) · 2026Article
- The Role of miR-501-3p in Abdominal Aortic Aneurysm Progression: A Pilot Study.Journal of cardiovascular translational research · 2026Article
- Peripheral microRNA signature in genetic frontotemporal dementia-findings from the GENFI initiative.GeroScience · 2026Article
- Exercise-associated microRNA programs as candidate modulators and biomarkers in glioblastoma: a narrative review.Discover oncology · 2026Review
- MicroRNA-VEGF axis in gastric cancer: a novel therapeutic frontier.Discover oncology · 2026Review
- The role of microRNAs on autophagy in cervical cancer: review.Discover oncology · 2025Review
- miRNA and Its Implications in the Treatment Resistance in Breast Cancer-Narrative Review of What Do We Know So Far.Non-coding RNA · 2025Review
- MSC-derived extracellular vesicles: Precision miRNA delivery for overcoming cancer therapy resistance.Regenerative therapy · 2025Review
- Integrated Network Analysis Decipher ZNF384-Related miR-20b-5p and miR-424-5p in Colon Adenocarcinoma.Cancer reports (Hoboken, N.J.) · 2025Article
- Non-coding RNAs, a double-edged sword in breast cancer prognosis.Cancer cell international · 2025Review
- A Cross-Sectional Pilot Analysis of Downregulated Circulating MicroRNAs in Laryngeal Cancer.Biomedicines · 2025Article
- Circulating levels of miR-20b-5p are associated with survival in cardiogenic shock.Journal of molecular and cellular cardiology plus · 2025Article
- Exosome-based miRNA delivery: Transforming cancer treatment with mesenchymal stem cells.Regenerative therapy · 2025Review
- Non-coding RNAs: emerging biomarkers and therapeutic targets in cancer and inflammatory diseases.Frontiers in oncology · 2025Review
- HTLV-1 and HTLV-2 infections significantly alter small RNA expression in asymptomatic carriers.Frontiers in medicine · 2025Article
- Targeting cancer via macrophage-derived exosomal miRNAs: implications for tumor progression and resistance.Frontiers in immunology · 2025Review
- M1 macrophage-derived exosomal miR-20b promotes radiosensitization via CCND1 in HPVFrontiers in oncology · 2025Article
- miR-29a-3p orchestrates key signaling pathways for enhanced migration of human mesenchymal stem cells.Cell communication and signaling : CCS · 2024Article
- MicroRNA Expression Profiling-Potential Molecular Discrimination of Papillary Thyroid Carcinoma Subtypes.Biomedicines · 2024Article
- Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies.Frontiers in cell and developmental biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 9 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs, as non-coding transcripts, modulate gene expression through RNA silencing under normal physiological conditions. Their aberrant expression has strongly associated with tumorigenesis and cancer development. MiR-20b is one of the crucial miRNAs that regulate essential biological processes such as cell proliferation, apoptosis, autophagy, and migration. Deregulated levels of miR-20b contribute to the early- and advanced stages of cancer. On the other hand, investigations emphasize the tumor suppressor ability of miR-20b. High-throughput strategies are developed to identify miR-20b potential targets, providing the proper insight into its molecular mechanism of action. Moreover, accumulated results suggest that miR-20b exerts its effects through diverse signaling pathways, including PI3K/AKT/mTOR and ERK axes. Restoration of the altered expression levels of miR-20b induces cell apoptosis and reduces invasion and migration. Further, miR-20b can be used as a biomarker in cancer. The current comprehensive review could lead to a better understanding of the miR-20b in either tumorigenesis or tumor regression that may open new avenues for cancer treatment. Video Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.